

9th Moores Cancer Center Industry/Academia Translational Oncology Symposium Agenda

April 11, 2013 | 8AM-6PM Goldberg Auditorium, Moores Cancer Center

Join distinguished investigators and clinicians from academia and top industry representatives in the discussion on the latest breakthroughs and applications in translational oncology. The talks feature important translational oncology discoveries and focus on industry/academia collaboration to overcome the translational gap in cancer drug development. An interactive panel session comprised of industry and academia panelists and a networking reception encourage further dialogue amongst all participants and speakers about collaborative translational oncology projects, driving innovation to better serve patients.

Organizers:

- Scott Lippman, MD, Director, Moores Cancer Center
- Ida Deichaite, PhD, Director, Industry Relations, Moores Cancer Center

Symposium Chair:

 David Cheresh, PhD, Associate Director for Translational Research and Professor of Pathology, Moores Cancer Center

Symposium Co-Chair:

Catriona Jamieson, MD, PhD, Director, Stem Cell Research Program, Associate Professor of Medicine, Moores Cancer Center

8:15AM	Registration and Continental Breakfast
8:50AM	Welcome and Overview
	 David Brenner, MD, UC San Diego School of Medicine Scott Lippman, MD, Moores Cancer Center
9:10AM	How to Outsmart Cancer Christian Rommel, PhD, Amgen Inc.
9:30AM	From bench to FDA approval at the Moores Cancer Center Anne Wallace, MD, Moores Cancer Center
9:45AM	 Mode of action of 2 novel therapeutic antibodies in clinical development: CD44 MAb RG7356 and Her3 MAb RG7116 Klaus Bosslet, PhD, Roche Diagnostics GmbH



10:05AM	 Part II: The Mouse That ROR'ed – Targeting Onco-Embryonic Antigens Thomas Kipps, MD, PhD, Moores Cancer Center
10:25AM	Break
10:40AM	 Translational Oncology activity of Kyowa Kirin, Discovery and development of CCR4 monoclonal antibody, mogamulizumab Yukimasa Shiotsu, PhD, Kyowa Hakko Kirin California Inc.
11:00AM	Cancer Stem Cell Research: From Bench, to Bedside and Back Catriona Jamieson, MD, PhD, Moores Cancer Center
11:30AM	Keynote Presentation
	 Cancer Treatment with NK Cell Lines: An Effective Alternative? Armand Keating, MD, FCRP(C), University of Toronto, Princess Margaret Hospital
12:00PM	Lunch
1:15PM	The potential of targeting microRNAs in cancer Neil Gibson, PhD, Regulus Therapeutics
1:30PM	Reversing tumor stemness and drug resistance David Cheresh, PhD, Moores Cancer Center
1:45PM	 Translational development of dual TORC1/TORC2 inhibitors and new insight into mechanism of action of the IMiDs Kristin Hege, MD, Celgene Corporation
2:00PM	Carfilzomib:Investigation in Small Cell Lung Cancer (SCLC) Paula O'Connor, MD, Onyx Pharmaceuticals
2:15PM	Identifying a Role for Hedgehog Signaling in GIST Jason Sicklick, MD, Moores Cancer Center
2:25PM	Genome-wide Mutational Analysis Reveals Core Signaling Pathways in Mucinous Neoplasms of the Appendix Olivier Harismendy, PhD, Moores Cancer Center



2:35PM	Next Generation Sequencing in the Oncology Clinic: The Foundation Medicine Experience Gary Palmer, Foundation Medicine Inc.
2:50PM	Center for Personalized Cancer Therapy: Making Individualized Therapy a Reality Razelle Kurzrock, MD, Moores Cancer Center
3:05PM	Break
3:30PM	Keynote Presentation
	Genomics and Individualized Medicine J. Craig Venter, PhD, J. Craig Venter Institute (JCVI)
4:00PM	Panel Discussion:
	Moderator: Steven Edelson, SciBX:Science-Business eXchange, BioCentury Publications
	Elona Baum, California Institute for Regenerative Medicine (CIRM)
	David Kabakoff, PhD, Sofinnova Ventures
	Mark Lappe, Inhibrx
	Joel Marcus, Alexandria Venture Investments
	Arturo Molina, FACP, Janssen Research & Development
5:00PM	Symposium Reception